Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study
Background: Despite calls for the use of real-world data, the rare diseases (RD) treatment landscape suffers from a scarcity of data referred to orphan medicinal products (OMP) use at the population level.Objectives: We aim to describe the characteristics and patterns of utilization of OMP in a siza...
Main Authors: | Monica Mazzucato, Cinzia Minichiello, Andrea Vianello, Laura Visonà dalla Pozza, Ema Toto, Paola Facchin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.940010/full |
Similar Items
-
Estimating mortality in rare diseases using a population-based registry, 2002 through 2019
by: Monica Mazzucato, et al.
Published: (2023-11-01) -
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
by: Francesca Gorini, et al.
Published: (2022-05-01) -
Correction: Estimating mortality in rare diseases using a population-based registry, 2002 through 2019
by: Monica Mazzucato, et al.
Published: (2024-02-01) -
A first description of the Colombian national registry for rare diseases
by: Heidi Eliana Mateus, et al.
Published: (2017-10-01) -
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
by: Entela Xoxi, et al.
Published: (2021-08-01)